Noe LGA Gesundheit Region Mitte GmbH
- Address
- lock Available on a paid plan
Noe LGA Gesundheit Region Mitte GmbH - Comprehensive Clinical Research Center
Noe LGA Gesundheit Region Mitte GmbH operates as a diversified clinical research center with extensive expertise across multiple therapeutic areas. The center demonstrates particular strength in oncology and hematology, with significant focus on advanced cancer treatments and innovative immunotherapies. Their research portfolio encompasses both solid tumors and hematologic malignancies, utilizing cutting-edge approaches including CAR-T cell therapy, bispecific antibodies, and combination immunotherapy regimens.
- Oncology: Multiple myeloma, lymphomas (DLBCL, follicular, mantle cell), breast cancer, melanoma, lung cancer, pancreatic cancer, and hepatocellular carcinoma studies
- Dermatology and Immunology: Psoriasis, atopic dermatitis, cutaneous lupus erythematosus, and squamous cell carcinoma research
- Cardiovascular and Metabolic Disorders: Heart failure, chronic kidney disease, hypertension, and coronary artery disease investigations
- Gastroenterology: Ulcerative colitis, Crohn's disease, eosinophilic esophagitis, and NASH clinical trials
The center maintains an active role in Phase II and Phase III clinical trials, evaluating novel therapeutic agents including monoclonal antibodies, small molecules, gene therapies, and antibody-drug conjugates. Their research extends to pediatric populations with studies in asthma and growth hormone deficiency, as well as specialized areas including peritoneal dialysis pharmacokinetics and neurological conditions such as refractory epilepsy. The center's commitment to comprehensive care is reflected in their participation in both early-stage safety studies and large-scale efficacy trials across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 169 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 150 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 38 by active trials.
lock +37 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG8trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Noe LGA Gesundheit Region Mitte GmbH
lock Showing 1 of 89 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma | Regeneron Pharmaceuticals Inc. | Phase II | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 169 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 10 | Unknown | 2018-08-24 | 2026-07-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.